Compare ESE & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESE | IBRX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 6.1B |
| IPO Year | N/A | N/A |
| Metric | ESE | IBRX |
|---|---|---|
| Price | $234.57 | $6.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $237.50 | $11.80 |
| AVG Volume (30 Days) | 174.9K | ★ 52.8M |
| Earning Date | 02-05-2026 | 03-02-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | ★ 193.06 | N/A |
| EPS | ★ 11.55 | N/A |
| Revenue | ★ $1,095,388,000.00 | $82,555,000.00 |
| Revenue This Year | $18.95 | $680.06 |
| Revenue Next Year | $6.91 | $90.18 |
| P/E Ratio | $20.18 | ★ N/A |
| Revenue Growth | 19.18 | ★ 1025.95 |
| 52 Week Low | $128.59 | $1.83 |
| 52 Week High | $234.43 | $8.28 |
| Indicator | ESE | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.68 | 67.79 |
| Support Level | $219.35 | $5.67 |
| Resistance Level | $229.41 | $6.75 |
| Average True Range (ATR) | 5.54 | 0.89 |
| MACD | 1.42 | 0.02 |
| Stochastic Oscillator | 94.69 | 60.90 |
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.